Gadolinium-based distinction agents (GBCAs) are broadly used in magnetic resonance imaging (MRI) to improve the visibility of blood vessels, tumors, inflammation, along with other internal buildings. Even though typically deemed Secure, concerns about GBCA toxicity have emerged in the last two decades—specially in sufferers with impaired kidney f